UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Crohn's Disease on Bone Metabolism In Vitro: A Role for Interleukin‐6

Journal of bone and mineral research, 2002-04, Vol.17 (4), p.695-702

2002

Volltextzugriff (PDF)

Detection of Group C Rotavirus in Infants with Extrahepatic Biliary Atresia

The Journal of infectious diseases, 1996-07, Vol.174 (1), p.8-15

1996

Volltextzugriff (PDF)

P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S445-S445

2019

Volltextzugriff (PDF)

P671 Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i802-i803

2023

Volltextzugriff (PDF)

P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i402-i403

2024

Volltextzugriff (PDF)

P566 Maintenance vedolizumab treatment in pediatric IBD: 54-week follow-up of the prospective multicenter VEDOKIDS study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1104-i1106

2024

Volltextzugriff (PDF)

P774 Maintenance treatment with vedolizumab in children with Inflammatory Bowel Disease: follow-up results from the prospective multicenter VEDOKIDS study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i904-i905

2023

Volltextzugriff (PDF)

DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S107-S108

2020

Volltextzugriff (PDF)

P655 Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn’s disease: Results from UniStar, a phase 1 study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S539-S540

2020

Volltextzugriff (PDF)

P089 Long ncRNA Landscape in the Rectum of Treatment Naïve Early Onset Ulcerative Colitis Highlights Association with Severity and Early and Late Disease Outcome, with Potential Role in Epithelial Metabolic Functions

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i187-i189

2022

Volltextzugriff (PDF)

OP32 Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S030-S030

2021

Volltextzugriff (PDF)

OP05 Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i005-i006

2022

Volltextzugriff (PDF)

P711 Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i608-i608

2022

Volltextzugriff (PDF)

P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn’s disease in healthy first-degree relatives

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i596-i597

2022

Volltextzugriff (PDF)

DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S127-S127

2020

Volltextzugriff (PDF)

P396 Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S304-S305

2018

Volltextzugriff (PDF)

OP19 Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S013-S014

2019

Volltextzugriff (PDF)

DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S035-S035

2018

Volltextzugriff (PDF)

P128 Development of the Paediatric Inflammatory Crohn's MRE Index (PICMI)- results from the ImageKids Study

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S158-S159

2018

Volltextzugriff (PDF)

DOP015 Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn disease

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S040-S040

2018

Volltextzugriff (PDF)

P426 Long-term safety of adalimumab in paediatric patients with Crohn's disease

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S243-S244

2014

Volltextzugriff (PDF)

P458 Impact of concomitant immunosuppressant use on adalimumab efficacy in children with moderately to severely active Crohn's disease: Results from IMAgINE 1

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S257-S258

2014

Volltextzugriff (PDF)

P367 Rate of and response to dose escalation in paediatric patients with Crohn's disease from IMAgINE 1

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S218-S218

2014

Volltextzugriff (PDF)

P385 Relationship between adalimumab concentration and efficacy for the induction of clinical remission in pediatric patients with moderate to severe Crohn's disease

Journal of Crohn's and colitis, 2013-02, Vol.7, p.S164-S164

2013

Volltextzugriff (PDF)

P384 Relationship between adalimumab concentration and efficacy for the maintenance of clinical remission in pediatric patients with moderate to severe Crohn's disease

Journal of Crohn's and colitis, 2013-02, Vol.7, p.S163-S163

2013

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Aktive Filter

KollektionOxford journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(108)

Publikationsform

Artikel
(126)
Reviews
(2)

Sprache

Englisch
(128)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Crohn's Disease on Bone Metabolism In Vitro: A Role for Interleukin‐6

Detection of Group C Rotavirus in Infants with Extrahepatic Biliary Atresia

P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience

P671 Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension

P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients

P566 Maintenance vedolizumab treatment in pediatric IBD: 54-week follow-up of the prospective multicenter VEDOKIDS study

P774 Maintenance treatment with vedolizumab in children with Inflammatory Bowel Disease: follow-up results from the prospective multicenter VEDOKIDS study

DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study

P655 Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn’s disease: Results from UniStar, a phase 1 study

P089 Long ncRNA Landscape in the Rectum of Treatment Naïve Early Onset Ulcerative Colitis Highlights Association with Severity and Early and Late Disease Outcome, with Potential Role in Epithelial Metabolic Functions

OP32 Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients

OP05 Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study

P711 Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment

P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn’s disease in healthy first-degree relatives

DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease

P396 Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension

OP19 Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis

DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry

P128 Development of the Paediatric Inflammatory Crohn's MRE Index (PICMI)- results from the ImageKids Study

DOP015 Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn disease

P426 Long-term safety of adalimumab in paediatric patients with Crohn's disease

P458 Impact of concomitant immunosuppressant use on adalimumab efficacy in children with moderately to severely active Crohn's disease: Results from IMAgINE 1

P367 Rate of and response to dose escalation in paediatric patients with Crohn's disease from IMAgINE 1

P385 Relationship between adalimumab concentration and efficacy for the induction of clinical remission in pediatric patients with moderate to severe Crohn's disease

P384 Relationship between adalimumab concentration and efficacy for the maintenance of clinical remission in pediatric patients with moderate to severe Crohn's disease

Aktive Filter

Suchergebnisse filtern